Search results | gilead

Gilead Sciences collaborates with Indian pharma partners for antiretroviral therapy

Gilead Sciences, together with Mylan Laboratories, Ranbaxy Laboratories Limited and Strides Arcolab, have entered into a pharma partners agreements to collaborate on promoting access to high-quality, low-cost generic versions of Gilead’s HIV medicine emtricitabine in developing countries – including single tablet regimens containing emtricitabine, and fixed-dose combinations of emtricitabine co-formulated with other Gilead HIV medicines. Under t…

Big pharma Gilead shake hands with AnaptysBio in antibody pharma partnering

Gilead Sciences, a big pharma company has inked a pharma partnering deal with AnaptysBio to develop antibody therapeutics. Antibodies generated by AnaptysBio using its proprietary SHM-XEL platform will be transferred to Gilead for worldwide development and commercialization. Under this pharma partnering agreement, Gilead has paid an up-front fee and will provide research funding to AnaptysBio through the antibody-generation process. AnaptysBio i…

In a M&A deal, Gilead Sciences acquired YM Biosciences for $510 million

Gilead Sciences and YM BioSciences have signed a definitive m&a agreement under which Gilead will acquire YM for U.S.$2.95 per share in cash. Under the terms of this m&a agreement, upon closing of the proposed transaction, shareholders of YM will receive U.S.$2.95 per common share in cash. Others including holders of warrants and stock options will receive a cash payment equal to the difference between U.S.$2.95 and the exercise price of…

Pharma licensing approval for Gilead Sciences, HIV drug Viread in EU

A pharma licensing authorization was approved for Gilead Sciences, HIV drug, Viread by European Commission. The first new indication  of the pharma licensing agreement permits the use of Viread in combination with other antiretroviral agents for the treatment of HIV-1 infected pediatric patients aged 2 to less than 18 years with nucleoside reverse transcriptase inhibitor (NRTI) resistance or toxicities precluding the use of first line pediatric…

Gilead and Cancer Genetics are biopharma partners

Cancer Genetics and Gilead Sciences, a big pharma company, are now biopharma partners where Cancer Genetics is providing clinical trial services and molecular profiling of chronic lymphocytic leukemia patients. CGI will leverage its SelectOne program that includes proprietary genomic assays in CLL, data and logistics management, and comprehensive CLIA- and CAP-accredited clinical laboratory testing. The trials cover both national and internation…

Big pharma Gilead signs R&D pharma partnering deal with Adimab

Adimab and Gilead Sciences, a top big pharma company  have initiated a pharma partnering research collaboration to identify therapeutic antibodies against two targets selected by Gilead. Adimab and Gilead have initiated a pharma partnering research program whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against up to two targets selected by Gilead. The pharma partnering agreement gives Gilead the opt…

Gilead Sciences: Partnering activity 2005-2013

Gilead Sciences announced over 60 partnering / licensing deals since 2005, with 20 deals in 2006 alone. Analysis of the partnering deals shows a strong emphasis on partnerships in infectives diseases. Abstracted from: Report: Partnering Agreements with Gilead Sciences 2005-2013 The number of partnering, collaborative R&D and licensing deals announced varied year on year with a decline recently from 14 deals announced in 2011 to 2 deals last…

Gilead buys biologics plant from Genentech

Gilead has announced that the company will purchase a clinical biologics manufacturing facility and certain process development assets located in Oceanside, California from Genentech. The agreement covers Genentech’s Oceanside Clinical Plant (OCP), as well as certain other process development assets. “This acquisition represents a unique opportunity to establish Gilead’s biologics process research and manufacturing capability while bringing on a…

Gilead Sciences partnering

Gilead Sciences is a top pharmaceutical company based in California, USA. The company was founded in 1987. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Since its inception in 1987, the company has primarily concentrated on antiviral drugs to treat patients infected with HIVhepatitis B, or influenza. In 2006, Gilead completed…

Gilead Sciences: M&A activity 2005-2013

Gilead Sciences has also announced 9 M&A deals since 2005, with the lead deals being the acquisition of Pharmasset and Myogen. Abstracted from: Report: Partnering Agreements with Gilead Sciences 2005-2013 Gilead Sciences is involved in M&A activity for growth similar to its peers in the list of top pharmaceutical companies. Gilead Sciences has on occasions sought growth through strategic acquisition, for example when acquiring Pharmasset…

ca300x150gif
biotech-china-300-x150newjpg
web300x150v2gif
RSS Feed Linked In Twitter

Latest Tweets

cp300x1502gif
cbpf14banner300x150jpg
emt14banner300x150jpg